Bridgebio Pharma Stock News

BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked.

- BridgeBio will host an investor call on June 13, 2022, at 4:30 pm ET to discuss the Phase 2b study results and the planned pivotal Phase 3 study design

BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

BridgeBio Pharma Inc (NASDAQ: BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and employee-related costs, and

PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic dise

First patient dosed in phase 1/2 ADventure study which is using BBP-631 for the treatment of patients with congenital adrenal hyperplasia; results from the study expected 2nd half of 2022.

BridgeBio Pharma Inc (NASDAQ: BBIO ) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness and wasting of the muscles in the arms and legs. The Company plans to engage with regulatory health bodies in 2022 to discuss potential paths to approval and intends to … Full story available on Benzinga.com

BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness

As per the terms of the agreement, Sentynl will acquire global rights to NULIBRY and will also be responsible for the ongoing development and commercialisation of NULIBRY in the US..With the acquisition of NULIBRY, Zydus aims at bridging unmet healthcare needs of children with rare and orphan paediatric diseases.

Zydus Lifesciences said its subsidiary had acquired US-based BridgeBio Pharma. Sentynl Therapeutics, a subsidiary of Zydus Lifesciences and BridgeBio Pharma, have done an asset purchase agreement for the sale of Nulibry (Fosdenopterin) for injection. The product is approved by the Food and Drug Administration (FDA) to decrease the risk of… The post Zydus to Acquire US-based BridgeBio Pharma appeared first on Equitypandit .

Under the terms of the agreement, Sentynl will acquire global rights to Nulibry, and will be responsible for its ongoing development and commercialisation in the US, and developing, manufacturing and commercialising Fosdenopterin globally The post Sentynl Therapeutics and BridgeBio Pharma announce asset purchase agreement for Nulibry appeared first on Express Pharma .

Sentynl will acquire the global rights to NULIBRY™ and will be responsible for its development and commercialisation in the US

NationalBusinessMirror is news portal, which provides news, opinions and in-depth analysis of business news and views to Indian corporates, MNCs and start-ups who could get latest yet trustworthy news and information instantly.

BridgeBio Pharma Inc (NASDAQ: BBIO ) has agreed to sell Nulibry (fosdenopterin) for injection to Sentynl Therapeutics Inc , owned by Zydus Lifesciences Ltd. Sentynl will provide cash payments upon the achievement of certain regulatory milestones. BridgeBio will be eligible to receive commercial milestone payments and tiered sales-based royalties. Specific terms were not disclosed. FDA-approved Nulibry is used to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A, … Full story available on Benzinga.com

BridgeBio Pharma (BBIO), a commercial-stage biotech company focused on genetic diseases, announced an agreement with Sentynl Therapeutics to sell its global rights for…